CN104812414A - 联合治疗 - Google Patents

联合治疗 Download PDF

Info

Publication number
CN104812414A
CN104812414A CN201380061379.0A CN201380061379A CN104812414A CN 104812414 A CN104812414 A CN 104812414A CN 201380061379 A CN201380061379 A CN 201380061379A CN 104812414 A CN104812414 A CN 104812414A
Authority
CN
China
Prior art keywords
cancer
combination
inhibitor
compound
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380061379.0A
Other languages
English (en)
Chinese (zh)
Inventor
舍望·多希
S·金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN104812414A publication Critical patent/CN104812414A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380061379.0A 2012-11-28 2013-11-25 联合治疗 Pending CN104812414A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730661P 2012-11-28 2012-11-28
US61/730,661 2012-11-28
PCT/US2013/071659 WO2014085318A1 (en) 2012-11-28 2013-11-25 Combination therapy

Publications (1)

Publication Number Publication Date
CN104812414A true CN104812414A (zh) 2015-07-29

Family

ID=49753505

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380061379.0A Pending CN104812414A (zh) 2012-11-28 2013-11-25 联合治疗

Country Status (12)

Country Link
US (1) US9408847B2 (enExample)
EP (1) EP2925365A1 (enExample)
JP (2) JP2016501221A (enExample)
KR (1) KR20150089053A (enExample)
CN (1) CN104812414A (enExample)
AU (4) AU2013352406A1 (enExample)
BR (1) BR112015012197A8 (enExample)
CA (1) CA2891938A1 (enExample)
HK (1) HK1211475A1 (enExample)
MX (1) MX2015006809A (enExample)
RU (1) RU2015125307A (enExample)
WO (1) WO2014085318A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020103922A1 (en) * 2018-11-23 2020-05-28 Ascentage Pharma (Suzhou) Co., Ltd. Novel pharmaceutical composition and use thereof

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103635189B (zh) * 2011-07-01 2016-05-04 诺华股份有限公司 用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗
US9464092B2 (en) 2013-03-15 2016-10-11 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
FI3834824T3 (fi) 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
BR112017004826A2 (pt) 2014-09-13 2017-12-12 Novartis Ag terapias de combinação de inibidores de alk
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3206711B1 (en) 2014-10-14 2023-05-31 Novartis AG Antibody molecules to pd-l1 and uses thereof
PE20171448A1 (es) 2015-03-10 2017-10-02 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
CN106336412A (zh) * 2015-07-10 2017-01-18 南开大学 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3156406A1 (en) * 2015-10-14 2017-04-19 ratiopharm GmbH Crystalline forms of ribociclib free base
CA3004138A1 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and tim-3 and their uses
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
JP7221699B2 (ja) * 2016-06-22 2023-02-14 エリプセス ファーマ エルティーディー Ａｒ＋乳癌の治療方法
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018081211A1 (en) * 2016-10-26 2018-05-03 Li George Y Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
RU2764724C2 (ru) * 2017-03-16 2022-01-19 ЭИСАЙ Р энд Д МЕНЕДЖМЕНТ КО., ЛТД. Комбинированная терапия для лечения рака молочной железы
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
MA49457A (fr) 2017-06-22 2020-04-29 Novartis Ag Molécules d'anticorps se liant à cd73 et leurs utilisations
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130232A1 (en) * 2010-04-13 2011-10-20 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130232A1 (en) * 2010-04-13 2011-10-20 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JOSÉ, BASELGA ET AL.: "Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer", 《THE NEW ENGLAND JOURNAL OF MEDICINE》 *
KRISTEN FOSTER ET AL.: "Dependence on PI3K/Akt signaling for malignant rhabdoid tumor cell survival", 《CANCER CHEMOTHER PHARMACOL》 *
RICHARD S FINN ET AL.: "PD 0332991, a selective cyclin D kinase 4/6 inhibiter, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro", 《BREAST CANCER RESEARCH》 *
YOSHIKI KATSUMI ET AL.: "Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》 *
郭青龙: "《肿瘤药理学》", 29 February 2008, 化学工业出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020103922A1 (en) * 2018-11-23 2020-05-28 Ascentage Pharma (Suzhou) Co., Ltd. Novel pharmaceutical composition and use thereof
US11452716B2 (en) 2018-11-23 2022-09-27 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition and use thereof

Also Published As

Publication number Publication date
WO2014085318A1 (en) 2014-06-05
BR112015012197A8 (pt) 2019-10-01
AU2013352406A1 (en) 2015-06-04
JP2016501221A (ja) 2016-01-18
MX2015006809A (es) 2015-08-06
RU2015125307A (ru) 2017-01-10
CA2891938A1 (en) 2014-06-05
AU2018200323A1 (en) 2018-02-01
US20150306104A1 (en) 2015-10-29
AU2016262781A1 (en) 2016-12-15
AU2019200881A1 (en) 2019-02-28
HK1211475A1 (en) 2016-05-27
KR20150089053A (ko) 2015-08-04
JP2019031500A (ja) 2019-02-28
EP2925365A1 (en) 2015-10-07
US9408847B2 (en) 2016-08-09
BR112015012197A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
US9408847B2 (en) Combination therapy
US20230405011A1 (en) Combination therapy for the treatment of cancer
EP3340990B1 (en) Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer
US20210186973A1 (en) Combination of ribociclib and dabrafenib for treating or preventing cancer
JP2022500388A (ja) 組み合わせ療法
TW201412316A (zh) 醫藥組合
US10328066B2 (en) Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
KR20160090814A (ko) Jak, cdk 및 pim의 억제제를 포함하는 조합 요법
US20180318275A1 (en) Combination therapy using pi3k inhibitor and mdm2 inhibitor
Yasuhiro et al. Novel oral derivative UD-017, a highly selective CDK7 inhibitor, exhibits anticancer activity by inducing cell-cycle arrest and apoptosis in human colorectal cancer
US10328065B2 (en) Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
US20180256557A1 (en) Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer
阿賀康弘 Novel Oral Derivative UD-017, a Highly Selective CDK7 Inhibitor, Exhibits Anticancer Activity by Inducing Cell-Cycle Arrest and Apoptosis in Human Colorectal Cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150729

WD01 Invention patent application deemed withdrawn after publication